A Triple Threat Against Ovarian Cancer: Os(II)-Pt(IV)-Ceritinib Conjugates for Photodynamic Therapy, Chemotherapy, and Immunogenic Cell Death Induction.

ABSTRACT: Metal-based anticancer agents offer unique opportunities to integrate multiple therapeutic modalities within a single molecular framework. Herein, we present the first Osmium(II)-Platinum(IV)-Ceritinib conjugate (Os-Pt-Cer) that synergistically combines photodynamic therapy (PDT), chemotherapy, and immunotherapy via immunogenic cell death (ICD) induction. This heterobimetallic complex features a photoactive osmium(II) polypyridyl core, a platinum(IV) prodrug derived from oxaliplatin, and the kinase inhibitor ceritinib as an axial ligand. Upon deep-red irradiation (λ = 740 nm), the conjugate exhibits potent antiproliferative activity in ovarian 2D cancer cells and 3D tumour spheroids, with IC₅₀ values in the low nanomolar range. In addition, Os-Pt-Cer effectively inhibits cancer

SUBMITTER: Redrado M 

PROVIDER: S-EPMC12668304 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature